Clinical and biochemical features of depression in Parkinson's disease.
Among 49 consecutive patients with Parkinson's disease, 40% were depressed according to DSM-III; they had major depression or dysthymic disorder accompanied by sleep disturbance, fatigue, psychomotor retardation, loss of self-esteem, and excessive guilt. During a 10-day dopamine-free period, lumbar puncture was performed to measure the metabolites of dopamine, serotonin, and norepinephrine. Patients were given an overnight dexamethasone suppression test, and the effects of thyrotropin-releasing hormone and L-dopa on plasma growth hormone and prolactin were examined. Level of CSF 5-hydroxyindoleacetic acid was lowest in parkinsonian patients with major depression and was related to psychomotor retardation and loss of self-esteem.
D000368:Aged; D003866:Depressive Disorder / Q000097:blood / Q000134:cerebrospinal fluid / Q000150:complications*; D003907:Dexamethasone; D013006:Growth Hormone / Q000097:blood; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid*; D007980:Levodopa; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications*; D011388:Prolactin / Q000097:blood; D011597:Psychomotor Performance / Q000502:physiology; D012649:Self Concept; D013973:Thyrotropin-Releasing Hormone
D007980:Levodopa; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D013973:Thyrotropin-Releasing Hormone; D003907:Dexamethasone; D011388:Prolactin; D013006:Growth Hormone; D006719:Homovanillic Acid